Sander van Tilburg
PhD student
My background
I obtained my bachelor’s degree in biology and master’s degree in biomedical sciences from Leiden University.
Currently, I work as a PhD student at the Department of Immunology at the Erasmus MC University Medical Centre, closely collaborating with the Department of Hospital Pharmacy and the Department of Neurology at the Erasmus MC.
My projects
The main goal of my project is to personalize treatment with intravenous immunoglobulin (IVIg) for patients with Guillain-Barré syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
To achieve this, we utilize non-linear mixed-effects models (NONMEM), the gold standard for pharmacokinetic and pharmacodynamics studies, to describe and predict concentration-time profiles for individual patients and identify factors that influence how the body handles IVIg.
The aim is to identify patients who respond poorly to the current standard dosing regimen and provide tailored treatment for every patient.
A list of research articles
-
Fc-gamma receptor (FcγR) polymorphisms and predisposition to develop GBS.
-
Study on GBS
FcγRs are important for the effector functions of immunoglobulin G (IgG) and are therefore expected to play a role in the pathophysiology of GBS. In this study, we identify the prevalence of genetic polymorphisms in the FCGR2/3 locus in patients with GBS using multiplex ligation-dependent probe amplification (MLPA). We aim to investigate whether certain genetic […]
-
-
PK-PD modelling in patients with CIDP.
-
Study on CIDP
The optimal maintenance dosing regimen of intravenous immunoglobulin (IVIg) varies between patients with CIDP. At present, there is only limited information available on the pharmacokinetics (PK) of IVIg treatment in patients with CIDP. In this study we want to describe the PK of IVIg induction and maintenance treatment in patients with CIDP using non-linear mixed […]
-
-
Should we individualize IVIG treatment in patients with GBS?
-
Study on GBS
A significant number of patients with GBS does not respond to the arbitrarily defined standard dosing regimen of intravenous immunoglobulin (IVIg). In this study, we aim to investigate the relationship between the pharmacokinetics (PK) – what the body does to the drug – and the clinical outcome (pharmacodynamics). The goal is to identify patients who […]
-
